NCT02647125

A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC

A Phase II Study of Comparing Huachansu Combination With Thoracic Radiotherapy Versus Radiotherapy Alone For Esophageal Squamous Cell Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 126 (actual)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This primary objective of the trial is to study whether the local control of Huachansu plus thoracic radiotherapy is better compared to thoracic radiotherapy alone for patients with esophageal squamous cell carcinoma. It's a phase II study, 134 patients are expected to be recruited into the trial.

Conditions

• Esophageal Squamous Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Huachansu	Huachansu 20 ml/m2/d, intervenous infusion, once a day, 5 times per week, during the period of radiation.
RADIATION	thoracic radiation	A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.

Timeline

• Start date: 2015-09-01
• Primary completion: 2022-09-01
• Completion: 2022-12-01
• First posted: 2016-01-06
• Last updated: 2024-11-26

Locations

1 site across 1 country: China